Rapsinski Lab

Thrilled to announce the @raplab.bsky.social is officially NIH K08 Funded!

Thrilled to have new people helping in the lab. Welcome @jscioli.bsky.social.!!

Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosa | Microbiology Spectrum Antibiotic resistance is a significant challenge for physicians trying to treat infections. The development of novel antibiotics to treat resistant infections has not been prioritized for decades, limiting treatment options for infections caused by many ...

Paper looking at how Avycaz (ceftazidime-avibactam) can select for cross resistance to other beta-lactam/beta-lactamase inhibitor combinations. @aleciarokes.bsky.social @vscooper.micropopbio.org @dariavantyne.bsky.social

Strong start to our P. aeruginosa research!

journals.asm.org/doi/10.1128/...

Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosa | Microbiology Spectrum Antibiotic resistance is a significant challenge for physicians trying to treat infections. The development of novel antibiotics to treat resistant infections has not been prioritized for decades, lim...

How does avi-caz treatment lead to broad-spectrum treatment failure? Our awesome Peds ID faculty and labbie @rapskiid.bsky.social shows how, by longitudinal sequencing, genotyping, and phenotyping. Congrats Glenn! @dariavantyne.bsky.social @aleciarokes.bsky.social

journals.asm.org/doi/10.1128/...

Many people, including academics, don't understand what F&A is for. Please share to help.

1) Translate to "overhead" in common business accounting:
60% IDC => 60/160 = 37.5% overhead (low!)

2) Infographic explaining what it's for, linked here:
www.cogr.edu/sites/defaul...